Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Je-Min | - |
dc.contributor.author | Sohn, Jung-Ho | - |
dc.contributor.author | Park, Tae-Yoon | - |
dc.contributor.author | Park, Jung-Won | - |
dc.contributor.author | Lee, Sang-Kyou | - |
dc.date.accessioned | 2022-07-16T16:07:49Z | - |
dc.date.available | 2022-07-16T16:07:49Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2012-04 | - |
dc.identifier.issn | 0165-2478 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/165986 | - |
dc.description.abstract | Nuclear factor of activated T cells (NFAT) is an important transcription factor for the production of interleukin (IL)-2 upon T-cell receptor (TcR) signaling. Therefore, inhibition of the NFAT-carcineurin pathway is an important target for inflammatory disease inhibition and graft rejection. A novel cell permeable peptide (CPP), Sim-2, has been identified from a human transcription factor, and Sim-2-CPP conjugated to beta-galactosidase or EGFP protein was efficiently delivered into cells in vitro and in vivo. A cell permeable form of the NFAT inhibitory peptide VIVIT (Sim-2-VIVIT) was synthesized and showed inhibitory effects on human CD4 or CD8 T-cell activation through NFAT transcriptional activity suppression and IL-2 inhibition. Intranasal administration of the Sim-2-VIVIT peptide in an ovalbumin (OVA)-induced murine asthma model alleviated peribronchial and perivascular infiltration of inflammatory cells in the lung and caused airway remodeling and airway hyper-responsiveness. These results suggest that cell permeable Sim-2-VIVIT peptide has clinical potential as an immunosuppressive agent for inflammatory diseases. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Je-Min | - |
dc.identifier.doi | 10.1016/j.imlet.2012.01.016 | - |
dc.identifier.scopusid | 2-s2.0-84862792153 | - |
dc.identifier.wosid | 000303224200005 | - |
dc.identifier.bibliographicCitation | IMMUNOLOGY LETTERS, v.143, no.2, pp.170 - 176 | - |
dc.relation.isPartOf | IMMUNOLOGY LETTERS | - |
dc.citation.title | IMMUNOLOGY LETTERS | - |
dc.citation.volume | 143 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 170 | - |
dc.citation.endPage | 176 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | TAT-FUSION PROTEINS | - |
dc.subject.keywordPlus | CYCLOSPORINE-A | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | TRANSDUCTION | - |
dc.subject.keywordPlus | CALCINEURIN | - |
dc.subject.keywordPlus | ASTHMA | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | INTERNALIZATION | - |
dc.subject.keywordPlus | NEPHROTOXICITY | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordAuthor | NFAT | - |
dc.subject.keywordAuthor | VIVIT | - |
dc.subject.keywordAuthor | Cell permeable peptide | - |
dc.subject.keywordAuthor | Asthma | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0165247812000508?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.